Biogen Pharmachem Industries Ltd (BIOGEN) — shareholding pattern, promoter holding, financials and share price
About Biogen Pharmachem Industries Ltd (BIOGEN)
Biogen Pharmachem Industries Ltd operates in the Other Financial Services industry, within the Financial Services sector. It trades on the NSE as BIOGEN and on the BSE under scrip code 531752. Its ISIN is INE703D01023.
Incorporated in 1995, Biogen Pharmachem Industries Ltd is in the business of trading in shares and securities. [1]
Biogen Pharmachem Industries Ltd is a versatile company with operations in stock broking, trading commodities like agro-based and precious metals, and generating wind power.
The company initially started its operations focusing on trading activities, particularly in present and future markets for commodities and shares.
Listed peers in Other Financial Services: Shyamkamal Investments Ltd, Supra Trends Ltd, Bervin Investments & Leasing Ltd, MPIL Corporation Ltd, Sumedha Fiscal Services Ltd, CMX Holdings Ltd.
Valuation & Returns
10 Jul 2026At ₹0.29 a share on 10 Jul 2026, Biogen Pharmachem Industries Ltd (BIOGEN) was valued at a price-to-earnings ratio of 32.15x against an industry P/E of 19.5x and a price-to-book of 0.33x on a book value of ₹0.87 per share as of Mar 2025. Solomo computes return on equity of 1.03% and return on capital employed of 0.97% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 32.15x
- Industry P/E
- 19.5x
- P/B
- 0.33x
- EPS (TTM)
- ₹0.01
- Book value / share
- ₹0.87
- ROE
- 1.03%
- ROCE
- 0.97%
- ROA
- 1.03%
- Debt / equity
- 0x
- Dividend yield
- 0%
- 52-week range
- ₹0.28 – ₹0.29
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Biogen Pharmachem Industries Ltd (BIOGEN) reported revenue of ₹2.56 crore, net profit of ₹0.86 crore and earnings per share of ₹0.01. That compares with revenue of ₹1.2 crore and net profit of ₹-0.29 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹0.58 crore and net profit ₹-0.36 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 2.47 | 0 | 2.38 | 1.2 | 2.56 |
| Net profit (₹ cr) | -0.01 | 0.46 | 1.93 | -0.29 | 0.86 |
| EPS (₹) | 0 | 0.01 | 0.03 | 0 | 0.01 |
| Measure | 1Y |
|---|---|
| Sales growth | -49.58% |
| Profit growth | -115.03% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 0% of Biogen Pharmachem Industries Ltd (BIOGEN) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 0%. Market capitalisation was ₹31 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: OMEGA COAL PRIVATE LIMITED 5.05%, PARICHAY INFRASTRUCTURE LIMITED 4.27%, RAMA SHIVA LEASE FINANCE PRIVATE LIMITED 3.69%, INTERFACE FINANCIAL SERVICES LIMITED 3.37%, SUBHRASHI AGENCIES PRIVATE LIMITED 2.45%, ANAMIKA DEALERS PRIVATE LIMITED 2.45%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 0% | - | - | 0% | 100% |
| Mar 2026 | 0% | - | - | 0% | 100% |
| Dec 2025 | 0% | - | - | 0% | 100% |
| Sep 2025 | 0% | - | - | 0% | 100% |
| Jun 2025 | 0% | - | - | 0% | 100% |
| Mar 2025 | 0% | - | - | 0% | 100% |
| Dec 2024 | 0% | - | - | 0% | 100% |
| Sep 2024 | 0% | - | - | 0% | 100% |